|
Anti-Endocrine Therapy = 165 (69.9)
|
|
Tamoxifen
|
75 (31.7)
|
|
Anastrozole (Arimidex)
|
45 (19)
|
|
Exemestane (Aromasin)
|
8 (3.3)
|
|
Letrozole (Femara)
|
32 (13.5)
|
|
Goserelin (Zoladex)
|
4 (1.6)
|
|
Aromatase Inhibitors
|
1 (0.4)
|
|
HER2 Therapy = 67 (28.4)
|
|
Trastuzumab (Herceptin)
|
66 (27.9)
|
|
Lapatinib (Tyverb)
|
1 (0.4)
|
|
Chemotherapy
|
194 (82.2)
|
|
AC: Adriamycin (Doxorubicin), Cyclophosphamide
|
49 (20.7)
|
|
Anthracycline
|
1 (0.4)
|
|
Docetaxel (Taxotere)
|
19 (8.0)
|
|
TAC: Docetaxel (Taxotere), Adriamycin (Doxorubicin) and Cyclophosphamide
|
22 (9.3)
|
|
TC: Docetaxel (Taxotere) and Cyclophosphamide
|
1 (0.4)
|
|
TCH: Docetaxel (Taxotere), Carboplatin and Trastuzumab
|
9 (3.8)
|
|
EC: Epirubicin and Cyclophosphamide
|
3 (1.2)
|
|
FEC: 5-Fluorouracil, Epirubicin and Cyclophosphamide
|
45 (19.0)
|
|
Paclitaxel (Taxol)/Taxane
|
36 (15.2)
|
|
FAC (or CAF): 5-Fluorouracil, Doxorubicin and Cyclophosphamide
|
4 (1.6)
|
|
Capecitabine (Xeloda)
|
3 (1.2)
|
|
5-Fluorouracil
|
1 (0.4)
|
|
Carboplatin
|
1 (0.4)
|
|
Unknown
|
46 (19.4)
|
